RAG1-SCID clinical study open in the Netherlands
Learn from Frank Staal what made him successful in the H2020 Recomb
March 8, 2021Successful Recomb Review meeting
May 18, 2021
We are proud to share a great milestone of the RECOMB project: the RAG1-SCID clinical study is about to begin in the Netherlands. We are very happy that, after 15 years of research, the stem cell gene therapy developed for RAG1-SCID patients will be used in the clinic and can offer a solution for patients across Europe. Read the full press release from LUMC Newsroom.
